Sponsored by
Very good results in a new Optune plus Pembrolizumab (Keytruda) trial for newly diagnosed glioblastoma. They reported median progression free of 11.2 months compared to the original Optune trial without Pembrolizumab which had 6.7 months median progression free survival. The trial for Pembrolizumab alone for recurrent Glioblastoma only had a 2.8 month progression free survival. This shows that Optune has an immunogenic effect, which the Pembrolizumab magnified. Hopefully we will see an even better result when they start adding a vaccine to the mix!